image_4_The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells.JPEG
The Ebola virus (EBOV) uses evasion mechanisms that directly interfere with host T-cell antiviral responses. By steric shielding of human leukocyte antigen class-1, the Ebola glycoprotein (GP) blocks interaction with T-cell receptors (TCRs), thus rendering T cells unable to attack virus-infected cells. It is likely that this mechanism could promote increased natural killer (NK) cell activity against GP-expressing cells by preventing the engagement of NK inhibitory receptors; however, we found that primary human NK cells were less reactive to GP-expressing HEK293T cells. This was manifested as reduced cytokine secretion, a reduction in NK degranulation, and decreased lysis of GP-expressing target cells. We also demonstrated reduced recognition of GP-expressing cells by recombinant NKG2D and NKp30 receptors. In accordance, we showed a reduced monoclonal antibody-based staining of NKG2D and NKp30 ligands on GP-expressing target cells. Trypsin digestion of the membrane-associated GP led to a recovery of the recognition of membrane-associated NKG2D and NKp30 ligands. We further showed that membrane-associated GP did not shield recognition by KIR2DL receptors; in accordance, GP expression by target cells significantly perturbed signal transduction through activating, but not through inhibitory, receptors. Our results suggest a novel evasion mechanism employed by the EBOV to specifically avoid the NK cell immune response.
History
References
- https://doi.org//10.1007/978-3-540-70962-6_15
- https://doi.org//10.2217/fvl.09.56
- https://doi.org//10.1016/j.virol.2003.12.014
- https://doi.org//10.1128/jvi.76.5.2518-2528.2002
- https://doi.org//10.1038/78645
- https://doi.org//10.1006/viro.2000.0601
- https://doi.org//10.1099/0022-1317-81-9-2155
- https://doi.org//10.1016/j.virol.2013.07.029
- https://doi.org//10.1371/journal.ppat.1001098
- https://doi.org//10.1038/319675a0
- https://doi.org//10.1126/science.1198687
- https://doi.org//10.1126/science.285.5428.727
- https://doi.org//10.1186/s13059-016-1137-3
- https://doi.org//10.1371/journal.pntd.0005645
- https://doi.org//10.1016/S0165-2478(99)00169-8
- https://doi.org//10.1089/vim.2004.17.390
- https://doi.org//10.1016/S0002-9440(10)63591-2
- https://doi.org//10.1089/vim.2014.0069
- https://doi.org//10.1016/j.celrep.2015.01.029
- https://doi.org//10.1016/S1074-7613(00)80350-7
- https://doi.org//10.1016/S1074-7613(00)80349-0
- https://doi.org//10.1034/j.1600-0854.2000.010405.x
- https://doi.org//10.1073/pnas.93.21.11327
- https://doi.org//10.1128/JVI.75.11.5197-5204.2001
- https://doi.org//10.1038/384432a0
- https://doi.org//10.1016/S0092-8674(00)81054-5
- https://doi.org//10.1128/JVI.02274-07
- https://doi.org//10.1016/j.jcv.2007.10.027
- https://doi.org//10.1073/pnas.0503594102
- https://doi.org//10.1016/S0042-6822(03)00233-2
- https://doi.org//10.1016/j.biocel.2005.02.018
- https://doi.org//10.1084/jem.20032141
- https://doi.org//10.1182/blood-2012-02-410795
- https://doi.org//10.1128/JVI.06346-11
- https://doi.org//10.1126/science.1259657
- https://doi.org//10.1056/NEJMoa1404505
- https://doi.org//10.1038/ni.1642
- https://doi.org//10.4049/jimmunol.173.4.2392
- https://doi.org//10.4049/jimmunol.1102267
- https://doi.org//10.1038/35059110
- https://doi.org//10.4049/jimmunol.1302079
- https://doi.org//10.1371/journal.pone.0008941
- https://doi.org//10.1016/S0022-1759(01)00359-3
- https://doi.org//10.1002/0471142735.im1107s93
- https://doi.org//10.4049/jimmunol.168.9.4531
- https://doi.org//10.1186/cc11838
- https://doi.org//10.3389/fmicb.2017.01571
- https://doi.org//10.1128/JVI.01462-09
- https://doi.org//10.1099/vir.0.81361-0
- https://doi.org//10.1016/S1473-3099(04)01103-X
- https://doi.org//10.1002/path.4456
- https://doi.org//10.1146/annurev.immunol.23.021704.115526
- https://doi.org//10.1038/nri3370
- https://doi.org//10.1126/scisignal.aad6182
- https://doi.org//10.1128/MCB.23.17.6291-6299.2003
- https://doi.org//10.1016/S1074-7613(00)80135-1
- https://doi.org//10.1002/immu.200390022
- https://doi.org//10.1084/jem.20022059
- https://doi.org//10.1016/j.cellimm.2006.03.002
- https://doi.org//10.3389/fmicb.2012.00429
- https://doi.org//10.1126/science.aab3920
- https://doi.org//10.1016/S1074-7613(00)80065-5
- https://doi.org//10.1007/s00251-010-0480-x
- https://doi.org//10.1016/S0140-6736(16)32621-6
- https://doi.org//10.1016/j.jcv.2016.11.005
- https://doi.org//10.1146/annurev.immunol.17.1.189
- https://doi.org//10.1038/ni1582
- https://doi.org//10.1038/srep45552
- https://doi.org//10.1007/978-1-60761-362-6_23
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity